Use access key #2 to skip to page content.
$4.80 -0.03 (-0.62%)
7/3/2008 1:00 PM

Exelixis, Inc. (EXEL)

CAPS Rating:
****

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

View All Commentary (EXEL)

Recs

8

Avatar ari21 (95.05) Submitted: 9/24/06 3:22 PM : Outperform Start Price: $8.99 EXEL Score: -42.49

this is a risky stock. Biotec company. Their drug pipeline, and the quality of the partnerships increases their chances to be a winning company in that risky sector.Only invest a small percent of your portfolio. Even with the positive resullts they got in phase I and II studies, this are preliminary results, only the phase III study results will count. See exel internet site for more information and buy with patience at the lowests price. In 3 or 4 years we see the real resullts

Report this Post Replies: 0 | Reply

Featured Broker Partners